As President Donald Trump vows to bridge the drug pricing gap between the U.S. and other developed countries with his “most ...

Pfizer CEO Albert Bourla has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing that his ...

Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...

Pfizer Inc. (NYSE: PFE) is one of the best wide moat stocks to buy now. On June 9, Pfizer, along with other drug ...

Pfizer and other drug companies met with the Trump administration to discuss lowering U.S. drug prices but no commitments ...

Despite an outcry from the biopharmaceutical industry, the U.K. government has kept the rebate rate under a national ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

(Reuters) -Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and ...

CEO Albert Bourla has reportedly said that the company has made no commitments during its meeting with the Trump ...

BioSpace did a deep dive into executive pay, examining the highest compensation packages, pay ratios and golden ...

Americas Society recognized Venezuela's opposition leader and two business executives with the Gold Medal for their impact on ...

The world’s largest meeting on cancer research has brought promising updates on treatment and prevention for colorectal ...